FDA Approves Sotatercept-csrk for Pulmonary Arterial Hypertension
Sotatercept-csrk is the first approved activin signaling inhibitor therapy for pulmonary arterial hypertension, which represents a new class of therapy.
Source: pharmacytimes.com
Page 17 - Saclay News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Saclay. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Saclay Today - Breaking & Trending Today
Phew, De-Icing Euclid's Instruments Worked. It's Seeing Better Now
The ESA developed a delicate operation to melt the thin layer of ice that fogged Euclid up. It worked, and Euclid is back in business.
Source: universetoday.com
How do globular clusters remain intact for so long?
The angular momentum of stars as they move in their orbits keeps the cluster from collapsing in on itself, but some collisions do occur.
Source: astronomy.com
FDA Approves Merck's WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1) -March 26, 2024 at 06:22 pm EDT
WINREVAIR is a breakthrough biologic for this rare, progressive disease WINREVAIR on top of background therapy significantly improved exercise capacity and multiple important secondary outcome...
Source: marketscreener.com
JWST spots oceans' worth of water evaporating from a distant disk
New observations of water evaporating and re-forming around a young star could shed light on the water that Earth hosts today.
Source: astronomy.com